United Therapeutics traded at $529.05 this Thursday July 16th, decreasing $2.74 or 0.52 percent since the previous trading session. Looking back, over the last four weeks, United Therapeutics lost 4.07 percent. Over the last 12 months, its price rose by 77.93 percent. Looking ahead, we forecast United Therapeutics to be priced at 517.94 by the end of this quarter and at 485.99 in one year, according to Trading Economics global macro models projections and analysts expectations.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.